These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 16864815

  • 1. A double-blind, controlled study of botulinum toxin A in chronic myofascial pain.
    Qerama E, Fuglsang-Frederiksen A, Kasch H, Bach FW, Jensen TS.
    Neurology; 2006 Jul 25; 67(2):241-5. PubMed ID: 16864815
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study.
    Göbel H, Heinze A, Reichel G, Hefter H, Benecke R, Dysport myofascial pain study group.
    Pain; 2006 Nov 25; 125(1-2):82-8. PubMed ID: 16750294
    [Abstract] [Full Text] [Related]

  • 3. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study.
    Harden RN, Cottrill J, Gagnon CM, Smitherman TA, Weinland SR, Tann B, Joseph P, Lee TS, Houle TT.
    Headache; 2009 May 25; 49(5):732-43. PubMed ID: 19178577
    [Abstract] [Full Text] [Related]

  • 4. The analgesic effect of botulinum-toxin A on postwhiplash neck pain.
    Braker C, Yariv S, Adler R, Badarny S, Eisenberg E.
    Clin J Pain; 2008 Jan 25; 24(1):5-10. PubMed ID: 18180629
    [Abstract] [Full Text] [Related]

  • 5. A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds.
    Affaitati G, Fabrizio A, Savini A, Lerza R, Tafuri E, Costantini R, Lapenna D, Giamberardino MA.
    Clin Ther; 2009 Apr 25; 31(4):705-20. PubMed ID: 19446144
    [Abstract] [Full Text] [Related]

  • 6. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.
    Ranoux D, Attal N, Morain F, Bouhassira D.
    Ann Neurol; 2008 Sep 25; 64(3):274-83. PubMed ID: 18546285
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of Single Botulinum Toxin Type A (Botox®) Injection for Relief of Upper Trapezius Myofascial Trigger Point: A Randomized, Double-Blind, Placebo-Controlled Study.
    Kwanchuay P, Petchnumsin T, Yiemsiri P, Pasuk N, Srikanok W, Hathaiareerug C.
    J Med Assoc Thai; 2015 Dec 25; 98(12):1231-6. PubMed ID: 27004309
    [Abstract] [Full Text] [Related]

  • 8. Injection in the cervical facet joint for shoulder pain with myofascial trigger points in the upper trapezius muscle.
    Tsai CT, Hsieh LF, Kuan TS, Kao MJ, Hong CZ.
    Orthopedics; 2009 Aug 25; 32(8):. PubMed ID: 19708635
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic use of botulinum toxin type A in treating neck and upper-back pain of myofascial origin: a pilot study.
    Lew HL, Lee EH, Castaneda A, Klima R, Date E.
    Arch Phys Med Rehabil; 2008 Jan 25; 89(1):75-80. PubMed ID: 18164334
    [Abstract] [Full Text] [Related]

  • 10. Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study.
    Graboski CL, Gray DS, Burnham RS.
    Pain; 2005 Nov 25; 118(1-2):170-5. PubMed ID: 16202527
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group.
    Headache; 2007 Apr 25; 47(4):486-99. PubMed ID: 17445098
    [Abstract] [Full Text] [Related]

  • 16. Topographical mapping and mechanical pain sensitivity of myofascial trigger points in the infraspinatus muscle.
    Ge HY, Fernández-de-Las-Peñas C, Madeleine P, Arendt-Nielsen L.
    Eur J Pain; 2008 Oct 25; 12(7):859-65. PubMed ID: 18203637
    [Abstract] [Full Text] [Related]

  • 17. Botulinum type A toxin complex for the relief of upper back myofascial pain syndrome: how do fixed-location injections compare with trigger point-focused injections?
    Benecke R, Heinze A, Reichel G, Hefter H, Göbel H, Dysport myofascial pain study group.
    Pain Med; 2011 Nov 25; 12(11):1607-14. PubMed ID: 21692970
    [Abstract] [Full Text] [Related]

  • 18. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study.
    Vadoud-Seyedi J, Simonart T.
    Br J Dermatol; 2007 May 25; 156(5):986-9. PubMed ID: 17286630
    [Abstract] [Full Text] [Related]

  • 19. The effect of small doses of botulinum toxin a on neck-shoulder myofascial pain syndrome: a double-blind, randomized, and controlled crossover trial.
    Ojala T, Arokoski JP, Partanen J.
    Clin J Pain; 2006 Jan 25; 22(1):90-6. PubMed ID: 16340597
    [Abstract] [Full Text] [Related]

  • 20. Are the effects of botulinum toxin injection on myofascial trigger points placebo effects or needling effects?
    Hsieh RL, Lee WC.
    Arch Phys Med Rehabil; 2008 Apr 25; 89(4):792-3; author reply 793. PubMed ID: 18374016
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.